Invest in Organisyl®
Fueling the future of life sciences with breakthrough 3D biomimetic technology
Organisyl® offers a disruptive, patented technology based on the physiological Extracellular Matrix (ECM). Functioning as a highly scalable core platform, our Physioscaffolds feed into multiple high-growth global markets: from biopharmaceutical development and personalized medicine to dermocosmetics and next-generation cellular agriculture.
We are currently opening new investment rounds to accelerate our international expansion, scale up our industrial production, and solidify our position as the global gold standard in 3D cell culture.
Why invest in Organisyl®?
– Unique & Patented Technology: A proprietary, disruptive innovation protected by robust intellectual property, offering unprecedented in vivo realism.
– Highly Scalable Business Model: A “Platform + Verticals” strategy. One core technology adapted to serve multiple highly lucrative, distinct industries.
– Double-Digit Market Growth: Positioned at the convergence of multi-billion-dollar industries experiencing exponential demand for physiological biomimetics.
– Market Readiness: Our solutions are not just theoretical; they have been developed over years of rigorous R&D and are already implemented in active scientific environments.
– An Experienced Leadership Team: A multidisciplinary team of scientific experts and business leaders with a proven track record of transforming visionary research into concrete commercial success.
Addressing massive, high-growth global markets
Our technology solves critical bottlenecks across four distinct, multi-billion-dollar industries.
Biopharma & Drug Discovery
The Opportunity: The global 3D cell culture market is projected to surpass $7 billion by 2034 (growing at a CAGR of >14%), while the broader predictive in vitro models market currently exceeds $20 billion.
Organisyl®’s Impact: The pharmaceutical industry loses billions annually on late-stage clinical trial failures due to inaccurate 2D and animal testing. Organisyl® perfectly mimics human tissue to predict drug efficacy and toxicity at the earliest stages of R&D, drastically de-risking pipelines and shortening time-to-market.
Preventive & Personalized Medicine
The Opportunity: The global regenerative medicine and precision health market is forecast to reach over $25 billion by 2030, driven by an aging population and the rise of chronic pathologies.
Organisyl®’s Impact: We empower the shift toward functional precision medicine. Our scaffolds allow clinicians and researchers to cultivate patient-specific cells under physiological conditions, creating biological “avatars” that enable highly tailored treatments and pioneer new, individualized therapeutic approaches.
Cosmetology & Dermocosmetics
The Opportunity: Driven by stringent global bans on animal testing and rising consumer demand for ethical products, the non-animal alternative testing market is experiencing sustained, rapid growth. The premium skincare and aesthetics market requires highly accurate efficacy data.
Organisyl®’s Impact: We provide the cosmetic industry with highly realistic, full-thickness 3D skin models. By enabling the precise testing of active ingredients without animal subjects, we ensure absolute product safety, substantiate marketing claims, and support ethical innovation.
Alternative Proteins & FoodTech
The Opportunity: The global cellular agriculture market is anticipated to grow at a massive CAGR of over 16% over the next decade as the world seeks sustainable food systems.
Organisyl®’s Impact: The primary bottleneck in cultivated meat and animal-free lipids is industrial-scale scaffolding. Organisyl® provides scalable, biomimetic scaffolds essential for efficient cellular agriculture. We supply the crucial 3D architecture required for proper muscle and fat tissue maturation, enabling the development of next-generation sustainable foods.
Who are we looking for?
To fuel our next phase of hyper-growth, we are looking to partner with visionary stakeholders who understand the transformative power of biotechnology. Our current opportunities are open to various investor profiles.
Sector-Specific Investors
Funds focused on deeptech, Life Sciences, Pharma, or FoodTech.
Institutional Investors
Venture Capital firms seeking high-yield, patented, and scalable biotech platforms.
Specialized Business Angels
Individual investors with a background in biotechnology or healthcare looking to support a paradigm-shifting innovation.
Strategic Corporate/R&D Investors
Industry leaders looking to secure a technological edge through equity partnerships.
Let’s build the future of biology together
Are you ready to invest in a technology that fundamentally upgrades how the world researches, heals, and feeds itself?